310 related articles for article (PubMed ID: 27997699)
1. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
4. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
[TBL] [Abstract][Full Text] [Related]
5. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
Abal M; Planaguma J; Gil-Moreno A; Monge M; Gonzalez M; Baro T; Garcia A; Castellvi J; Ramon Y Cajal S; Xercavins J; Alameda F; Reventos J
Histol Histopathol; 2006 Feb; 21(2):197-204. PubMed ID: 16329044
[TBL] [Abstract][Full Text] [Related]
10. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
11. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
[TBL] [Abstract][Full Text] [Related]
12. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
14. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.
Rosa-Rosa JM; Leskelä S; Cristóbal-Lana E; Santón A; López-García MÁ; Muñoz G; Pérez-Mies B; Biscuola M; Prat J; Esther O; Soslow RA; Matias-Guiu X; Palacios J
Mod Pathol; 2016 Nov; 29(11):1390-1398. PubMed ID: 27491810
[TBL] [Abstract][Full Text] [Related]
16. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
17. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
Schultheis AM; Ng CK; De Filippo MR; Piscuoglio S; Macedo GS; Gatius S; Perez Mies B; Soslow RA; Lim RS; Viale A; Huberman KH; Palacios JC; Reis-Filho JS; Matias-Guiu X; Weigelt B
J Natl Cancer Inst; 2016 Jun; 108(6):djv427. PubMed ID: 26832770
[TBL] [Abstract][Full Text] [Related]
18. KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
Rudd ML; Hansen NF; Zhang X; Urick ME; Zhang S; Merino MJ; ; Mullikin JC; Brody LC; Bell DW
PLoS One; 2022; 17(1):e0251286. PubMed ID: 35081118
[TBL] [Abstract][Full Text] [Related]
19. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
